key: cord-0963501-4fmhhcny
authors: Collins, Sean P.; Chappell, Mark C.; Files, D. Clark
title: The Renin–Angiotensin–Aldosterone System in COVID-19–related and Non–COVID-19–related Acute Respiratory Distress Syndrome: Not So Different after All?
date: 2021-03-30
journal: Am. j. respir. crit. care med
DOI: 10.1164/rccm.202108-1904ed
sha: c0ff7f888fe00b648f68790a0b26d981e6b80bd9
doc_id: 963501
cord_uid: 4fmhhcny

nan

samples). Using immunohistochemical staining, the major finding was that ACE and ACE2 expression in the lungs of COVID-19-negative and -positive ARDS were remarkably similar. They found increased lung ACE2 and reduced lung ACE expression in patients with COVID-19-positive and -negative ARDS compared with uninjured control subjects. ACE2 was increased selectively in pulmonary endothelial cells, whereas ACE was downregulated in both endothelial and type II epithelial cells (AT2) in the ARDS cohorts. One difference between COVID-19-positive and -negative ARDS groups was that AT2 cell numbers were reduced in COVID-19-positive compared with COVID-19-negative ARDS. This finding could represent viral induced apoptosis of AT2 cells in the COVID-19 cohort. Alternatively, because the non-COVID-19 ARDS samples were obtained from patients undergoing open lung biopsy (some of whom presumably recovered) as compared with the postmortem COVID-19 samples, the increased AT2 cells in non-COVID-19 ARDS may just represent AT2 hyperplasia, a known mechanism of lung injury repair (7) . Serum concentrations revealed trends consistent with tissue expression, including increased concentrations of ACE2 and decreased concentrations of ACE, in both COVID-19-and non-COVID-19-related ARDS relative to controls. Consistent with increased ACE2 expression, the authors found increased Ang-(1-7) concentrations in COVID-19-related and non-COVID-19-related ARDS.

These findings may be counterintuitive to the presumed pathophysiology related to ACE2-induced endocytosis as a result of SARS-CoV-2 binding and relative imbalance favoring AngII activity relative to Ang-(1-7) (8). This imbalance has been suspected of being proinflammatory and vasoconstrictive, perpetuating acute lung injury in patients hospitalized with SARS-CoV-2 infection. Furthermore, although this has been thought to be unique to COVID-19-related ARDS, findings by Gerard and colleagues suggest this may be ubiquitous to ARDS regardless of etiology. However, as the authors suggest, their results may be explained by several possibilities, and similar results have been seen in other case series comparing patients who died from respiratory failure from COVID-19 with those who died from respiratory failure from influenza (9). One potential explanation for increased ACE2 in the lungs of patients with COVID-19 could be that this represents increased susceptibility to both COVID-19 infection and disease severity. Alternatively, their findings could also represent an end-stage process, associated with a relatively late compensatory upregulation of ACE2 in lung tissue and sera only seen late in the course of SARS-CoV-2 infection. Perhaps serial sampling of the alveolar space with BAL might provide insight on this issue. Without sampling over the time course of COVID-19 infection, it will be hard to disentangle whether these findings represent an adaptive or maladaptive response.

It is also important to recognize that quantification of angiotensins is associated with specific challenges. Significant metabolism and degradation of the peptides can occur ex vivo during serum incubations because of the presence of various angiotensinsases in blood. A preferred method to minimize peptide metabolism is to use an inhibitor cocktail, preventing metabolism (and clotting of blood), and solid-phase extraction (C18, C8, or phenyl matrix) of the plasma fraction to concentrate the peptides and remove interfering substances prior to assay using radioimmunoassays (10) . Previous pilot studies using this technique reported circulating levels of AngII in the 20 pM range (20 pg/mL) among patients negative or positive for COVID-19 with moderate and severe respiratory failure (8) . In contrast, Gerard and colleagues found AngII undetectable (,0.3 pg/mL) in the majority of their serum samples for both control and COVID-19 groups, perhaps reflecting ex vivo metabolism of AngII in the serum samples.

Their findings, if further validated, have several implications for both COVID-19-related and non-COVID-19-related ARDS. First, although cellular entry and destruction of ACE2 has been implicated in COVID-19-related ARDS, its contributions to non-COVID-19-related ARDS have been thought to be less relevant. However, if ACE2 plays a key role in non-COVID-19-related ARDS, therapeutic approaches in patients with COVID-19-related ARDS may have similar efficacy in non-COVID-19-related ARDS. Second, it would be important to carefully evaluate ACE2 expression in the lung compartment (early versus late after symptom onset) and how serial measurements of angiotensins and peptidases change over time as well as before and after therapy in patients hospitalized with COVID-19-related ARDS. These investigations may shed light on the interplay of clinical severity, the time course of illness, and response to treatment. Using therapies from successful COVID-19 clinical trials and applying them to non-COVID-19 ARDS would be a tremendous downstream impact from clinical trials conducted during the pandemic. These data from Gerard and colleagues are an important step in uncovering the role of the RAAS in COVID-19 and ARDS.

Author disclosures are available with the text of this article at www.atsjournals.org. 

Angiotensin signalling in pulmonary fibrosis

Acute respiratory distress syndrome

Acute respiratory distress in adults

ARDS subphenotypes: understanding a heterogeneous syndrome

Physiological and biological heterogeneity in COVID-19-associated acute respiratory distress syndrome

Increased angiotensin-converting enzyme 2 and loss of alveolar type II cells in COVID-19-related acute respiratory distress syndrome

Alveolar type 2 progenitor cells for lung injury repair

A pilot study to assess the circulating renin-angiotensin system in COVID-19 acute respiratory failure

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

Concerns on the specificity of commercial ELISAs for the measurement of angiotensin (1-7) and angiotensin II in human plasma

Longitudinal epidemiologic studies have shown that long-term exposure to particulate matter (PM) air pollution can be associated with steeper loss of lung function over time (1) . Metabolic syndrome (MetSyn), which is characterized by a combination of metabolic risk factors such as dyslipidemia, hypertension, large abdominal girth, and poor glycemic control (2), has also been associated with lower lung volumes, more rapid function decline, and developing asthma (3) (4) (5) . Less is known, however, about how PM exposure and metabolic risk factors longitudinally synergize in causing respiratory disease. This is an important public health question given the overwhelming prevalence of obesity and MetSyn and the wide population exposure